Paediatrics articles within Nature Reviews Clinical Oncology

Featured

  • News & Views |

    The International Society of Paediatric Oncology (SIOP)–Paediatric Oncology in Developing Countries (PODC) Collaborative Wilms Tumour Africa project delivered treatment in eight centres across five countries in sub-Saharan Africa. Setting up a collaboration like this is easier said than done, and herein we share the lessons we learned along the way.

    • Trijn Israels
    •  & Elizabeth M. Molyneux

  • Opinion |

    Numerous calls for improvement in the quality of follow-up care provided to cancer survivors, particularly survivors of childhood cancer have been issued by key health organizations in the USA; the Passport for Care (PFC) is a web-based support system for survivor care that was developed in response. In this Perspectives, key individuals involved in the development of this support tool for clinical decision making outline the programme, describe how it compares with similar guidance tools, and discuss the potential implications of the PFC for survivorship care. The challenges encountered and the lessons learned during development and deployment of the PFC are also highlighted.

    • David G. Poplack
    • , Michael Fordis
    •  & Marc E. Horowitz

  • Review Article |

    Medulloblastoma is the most-common form of paediatric brain cancer. Advances in our understanding of the molecular basis of medulloblastoma indicate that it is not a single disease, but a collection of four distinct molecular tumour subtypes. This knowledge has important implications for medulloblastoma research and treatment. In this Review, the characteristic demographic, clinical and genetic features of the four molecular subtypes of medulloblastoma are described, and the implications of molecular distinctions on therapy are discussed.

    • Amar J. Gajjar
    •  & Giles W. Robinson

  • Opinion |

    Many cancers, particularly those that arise in childhood, have a hereditary component. In this Perspectives article, the authors provide their views on how the increased adoption of high-throughput DNA sequencing technologies, which produce vast genetic data that is not necessarily limited to known cancer-susceptibility loci, and cancer surveillance strategies are influencing the clinical management of familial cancer. Important ethical issues relating to genetic counselling and disclosure of genetic information on disease susceptibility are discussed, and strategies for approaching these ethical dilemmas are proposed.

    • Nardin Samuel
    • , Anita Villani
    •  & David Malkin

  • Viewpoint |

    In this Viewpoint, four key opinion leaders discuss the slow rate of drug development in paediatric oncology, which must be addressed in a meaningful way if we are to make progress. They discuss a range of aspects, from clinical trial design and biomarker discovery to regulatory amendments and input from industry, government, academia, non-governmental organizations and patient advocacy groups.

    • Peter C. Adamson
    • , Peter J. Houghton
    •  & Kathy Pritchard-Jones

  • Review Article |

    In this Review, the authors describe the pathophysiological effects of chemotherapy and radiotherapy that affect the heart and treatment-related cardiovascular effects in children with cancer. They argue that 5-year event-free oncological survival is no longer the paradigm of successful treatment of childhood cancer; instead overall quality of life is and maximizing oncological efficacy while minimizing toxicity and late-effects should be the ultimate goal.

    • Steven E. Lipshultz
    • , Thomas R. Cochran
    •  & Tracie L. Miller

  • Review Article |

    There is a general belief that paediatric palliative care should be provided only when no hope for the cure exists. This Review discusses how paediatric palliative care should be applied consistently and concurrently with other therapies regardless of the prognosis or disease stage, to ensure that the best possible care for children and their families is provided.

    • Elisha Waldman
    •  & Joanne Wolfe

  • News & Views |

    The optimal age-specific treatment approach for adolescents with Hodgkin lymphoma (HL) is controversial. Here we discuss the results of a recent retrospective analysis that compared the outcomes for adolescents with those of young adults with HL treated with regimens normally recommended for adults. The investigators conclude that adult treatment protocols are a safe and effective treatment option for adolescents with HL, but the results do not consider late treatment toxicity that may impact quality of life and survival.

    • John T. Sandlund
    •  & Melissa M. Hudson

Browse broader subjects

Browse narrower subjects

Browse Paediatrics across other nature.com journals